Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced strategic development initiatives to expand the capabilities of its Aquadex SmartFlow® System into a broader extracorporeal therapy platform. The program is intended to enhance the system's operating parameters by supporting higher blood flow rates, expanded operating pressure ranges, and broader compatibility with advanced extracorporeal therapies, creating the foundation for future therapeutic applications beyond ultrafiltration.